Highlights

  • GeoVax Labs shares closed at US$2.02 on 16 November 2026, up 18.48%, with 7.17 million shares traded in the session.
  • Relative Volume of about 75 indicated trading far above the stock's usual level, reflecting intense activity around the Vaccine developer.
  • The lead program, GEO-MVA, targets mpox and smallpox, and a Phase 3 immuno-bridging study is planned for a later date.
  • The company presented at World Vaccine Congress Europe between 19 and 22 October 2026, outlining its vaccine and oncology platforms.

A vaccine developer based in Atlanta saw its trading activity jump on Monday. GeoVax Labs, Inc. (NASDAQ:GOVX) closed at US$2.02 on 16 November 2026, up 18.48%, as 7.17 million shares traded. Volume ran at roughly 75 times the usual level, an unusually high reading for the clinical-stage biotech.

An Unusually Active Session

The gain came with very heavy turnover, as relative volume reached about 75. The company's latest disclosed developments did not point to a single announcement on the day, so the move is presented as a general rise in trading activity.

GeoVax has completed reverse share splits in the past, so historical share prices are not directly comparable with current quotes.

Large relative volume is typical when sentiment turns quickly in low-priced biotech names, and price levels can change sharply from session to session.

GEO-MVA for Mpox and Smallpox

GEO-MVA is the company's modified vaccinia Ankara vaccine candidate for mpox and smallpox. The company has planned a Phase 3 immuno-bridging study, a trial design that compares immune responses with an established product, with timing outlined for the fourth quarter of 2026 or the second half of 2026 depending on the report.

The program is positioned as a potential addition to biodefence and public-health stockpiles. Progress depends on regulatory feedback, funding and the outcome of the planned study.

Mpox is a viral disease that spread internationally in recent years, and smallpox vaccines are held in government stockpiles for preparedness. Developers of such products often depend on government contracts and regulatory pathways that differ from conventional consumer vaccines.

Gedeptin and Other Platforms

Beyond infectious disease, GeoVax is developing Gedeptin, a gene-directed enzyme prodrug therapy for solid tumours. The dual focus on vaccines and oncology gives the company two separate development paths.

From 19 to 22 October 2026, GeoVax presented at World Vaccine Congress Europe, where it discussed its portfolio with industry participants.

Gene-directed enzyme prodrug therapy delivers a gene into tumour cells so that a harmless drug is converted into a cancer-killing agent inside the tumour, an approach intended to limit exposure of healthy tissue.

Funding, Risks and What to Watch

Clinical-stage companies rely on Capital Markets to fund trials, and GeoVax has used private placements and warrants in the past to raise money. Further financing can dilute existing holders.

Investors may follow regulatory discussions on the Phase 3 design, any government or partner funding for GEO-MVA and updates on Gedeptin. Biotech share prices can move sharply on trial news, funding events and sector sentiment.

As a clinical-stage company without approved products, GeoVax's valuation reflects expectations for its pipeline rather than current sales.